Effects of aerobic exercise training in anemic cancer patients receiving darbepoetin alfa: A randomized controlled trial

Oncologist

Volumn 13, Issue 9, 2008, Pages 1012-1020

  Courneya, Kerry S ^a   Jones, Lee W ^b   Peddle, Carolyn J ^a   Sellar, Christopher M ^a   Reiman, Tony ^a   Joy, Anil A ^a   Chua, Neil ^a   Tkachuk, Linda ^c   Mackey, John R ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c CROSS CANCER INSTITUTE   (Canada)

Author keywords

Anemia; Erythropoiesis stimulating agent; Exercise; Fatigue; Fitness; Physical activity

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ADULT; AEROBIC EXERCISE; AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FATIGUE; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NEOPLASM; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

EID: 52949123606     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0017     Document Type: Article

References (41)

1. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst 1999;91:1616-1634.
2. Wilson J, Yao GL, Raftery J et al. A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess 2007;11:1-202, iii-iv.
3. Bokemeyer C, Aapro MS, Courdi A et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007;43:258-270.
4. Siddiqui MA, Keating GM. Darbepoetin alfa: A review of its use in the treatment of anaemia in patients with cancer receiving chemotherapy. Drugs 2006;66:997-1012.
5. Rizzo JD, Somerfield MR, Hagerty KL et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 2008;26:132-149.
6. Leyland-Jones B, Semiglazov V, Pawlicki M et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol 2005;23:5960-5972.
7. Wright JR, Ung YC, Julian JA et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007;25:1027-1032.
8. Pirker R. Safety considerations for erythropoietin treatment in patients with cancer. Expert Opin Drug Saf 2007;6:63-69.
9. Glaspy JA, Tchekmedyian NS. Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy. Oncology (Williston Park) 2002;16(suppl 11):23-29.
10. Glaspy J, Vadhan-Raj S, Patel R et al. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: The 20030125 Study Group trial. J Clin Oncol 2006;24:2290-2297.
11. Senecal FM, Yee L, Gabrail N et al. Treatment of chemotherapy-induced anemia in breast cancer: Results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly. Clin Breast Cancer 2005;6:446-454.
12. Conn VS, Hafdahl AR, Porock DC et al. A meta-analysis of exercise interventions among people treated for cancer. Support Care Cancer 2006;14:699-712.
13. McNeely ML, Campbell KL, Rowe BH et al. Effects of exercise on breast cancer patients and survivors: A systematic review and meta-analysis. CMAJ 2006;175:34-41.
14. Mutrie N, Campbell AM, Whyte F et al. Benefits of supervised group exercise programme for women being treated for early stage breast cancer: Pragmatic randomised controlled trial. BMJ 2007;334:517.
15. Courneya KS, Segal RJ, Mackey JR et al. Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: A multicenter randomized controlled trial. J Clin Oncol 2007;25:4396-4404.
16. Drouin JS, Young TJ, Beeler J et al. Random control clinical trial on the effects of aerobic exercise training on erythrocyte levels during radiation treatment for breast cancer. Cancer 2006;107:2490-2495.
17. Silverberg DS, Wexler D, Blum M et al. Effect of correction of anemia with erythropoietin and intravenous iron in resistant heart failure in octogenarians. Isr Med Assoc J 2003;5:337-339.
18. Cella D, Eton DT, Lai JS et al. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 2002;24:547-561.
19. Jones LW, Eves ND, Mackey JR et al. Safety and feasibility of cardiopulmonary exercise testing in patients with advanced cancer. Lung Cancer 2007;55:225-232.
20. Weisman IM, Zeballos RJ. Clinical exercise testing. Clin Chest Med 2001;22:679-701, viii.
21. Godin G, Shephard RJ. A simple method to assess exercise behavior in the community. Can J Appl Sport Sci 1985;10:141-146.
22. Bohlius J, Wilson J, Seidenfeld J et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2006;3:CD003407.
23. Ross SD, Allen IE, Henry DH et al. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: A systematic review of the literature. Clin Ther 2006;28:801-831.
24. Bennett JA, Winters-Stone K, Nail L. Conceptualizing and measuring physical functioning in cancer survivorship studies. Oncol Nurs Forum 2006;33:41-49.
25. Gulati M, Pandey DK, Arnsdorf MF et al. Exercise capacity and the risk of death in women: The St James Women Take Heart Project. Circulation 2003;108:1554-1559.
26. Daneryd P, Svanberg E, Körner U et al. Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: A randomized prospective study. Cancer Res 1998;58:5374-5379.
27. Painter P. Physical functioning in end-stage renal disease patients: Update 2005. Hemodial Int 2005;9:218-235.
28. Palazzuoli A, Silverberg D, Iovine F et al. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J 2006;152:1096.e9-15.
29. Ponikowski P, Anker SD, Szachniewicz J et al. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: A randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2007;49:753-762.
30. Jones AM, Carter H. The effect of endurance training on parameters of aerobic fitness. Sports Med 2000;29:373-386.
31. Dimeo F, Knauf W, Geilhaupt D et al. Endurance exercise and the production of growth hormone and haematopoietic factors in patients with anaemia. Br J Sports Med 2004;38:e37.
32. Duda K, Zoladz JA, Majerczak J et al. The effect of exercise performed before and 24 hours after blood withdrawal on serum erythropoietin and growth hormone concentrations in humans. Int J Sports Med 2003;24:326-331.
33. Berg U, Bang P. Exercise and circulating insulin-like growth factor I. Horm Res 2004;62(suppl 1):50-58.
34. Christ ER, Cummings MH, Westwood NB et al. The importance of growth hormone in the regulation of erythropoiesis, red cell mass, and plasma volume in adults with growth hormone deficiency. J Clin Endocrinol Metab 1997;82:2985-2990.
35. Kaushansky K. Lineage-specific hematopoietic growth factors. N Engl J Med 2006;354:2034-2045.
36. Flamm SD, Taki J, Moore R et al. Redistribution of regional and organ blood volume and effect on cardiac function in relation to upright exercise intensity in healthy human subjects. Circulation 1990;81:1550-1559.
37. Kasapis C, Thompson PD. The effects of physical activity on serum C-reactive protein and inflammatory markers: A systematic review. J Am Coll Cardiol 2005;45:1563-1569.
38. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-2098.
39. Smith RE Jr, Aapro MS, Ludwig H et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 2008;26:1040-1050.
40. Henke M, Laszig R, Rube C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-1260.
41. Mitka M. FDA sounds alert on anemia drugs. JAMA 2007;297:1868-1869.